Heparin-induced Thrombocytopenia Clinical Trial
Official title:
Heparin-Induced Thrombocytopenia : Development and Validation of a Predictive Clinical Score: a Prospective Multicenter Study Under the Auspices of the French Haemostasis and Thrombosis Study Group (GEHT)in Cooperation With the French Association of Regional PharmacoVigilance Center (AFCRPV)
Although Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin treatment,
it results in a high rate of morbidity and mortality, the cumulative rate of thrombosis
recurrence, amputation and death approaching 52 % at one month if no specific treatment is
initiated. It is therefore vital to diagnose HIT as early and as reliably as possible to
permit appropriate management of this rare condition.
During the acute phase of HIT, clinicians and biologists can only suspect this complication
with a greater or lesser degree of confidence. Clinical data are not sufficiently sensitive
or specific to confirm or refute thr diagnosis of HIT.
Purpose : To create and validate a score predicting the diagnosis of HIT ;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00759083 -
Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients
|
Phase 4 | |
Completed |
NCT00412464 -
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
|
Phase 1 | |
Completed |
NCT00456326 -
Heparin-Induced Thrombocytopenia Registry
|
N/A | |
Terminated |
NCT00673439 -
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
|
Phase 2 | |
Active, not recruiting |
NCT00198575 -
A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients
|
N/A | |
Completed |
NCT00283322 -
Heparin Antibodies in Intensive Care Unit Patients (HAICU)
|
N/A | |
Not yet recruiting |
NCT05586854 -
Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia
|
N/A | |
Not yet recruiting |
NCT03269019 -
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
|
N/A | |
Not yet recruiting |
NCT06066762 -
Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
|
||
Terminated |
NCT03809481 -
Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban
|
Phase 3 | |
Completed |
NCT05325346 -
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
|
Phase 1 | |
Recruiting |
NCT02717039 -
Pharmacogenomics of Heparin-Induced Thrombocytopenia
|
||
Completed |
NCT02526485 -
Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
|
||
Recruiting |
NCT05783895 -
Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
|
||
Not yet recruiting |
NCT04782843 -
Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
|
||
Completed |
NCT00198588 -
Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia
|
Phase 3 | |
Recruiting |
NCT04842760 -
PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
|
||
Terminated |
NCT01598168 -
Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia
|
Phase 3 | |
Completed |
NCT01654848 -
Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients
|
N/A | |
Withdrawn |
NCT00603824 -
Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)
|
Phase 4 |